An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
NCT ID: NCT01224093
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
219 participants
OBSERVATIONAL
2010-10-31
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
First line
Chemotherapy
as prescribed
rituximab [MabThera/Rituxan]
as prescribed
Relapsed/refractory
Chemotherapy
as prescribed
rituximab [MabThera/Rituxan]
as prescribed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chemotherapy
as prescribed
rituximab [MabThera/Rituxan]
as prescribed
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* B cell-lineage chronic lymphocytic leukaemia (B-CLL)
* Prescribed with MabThera/Rituxan in combination with chemotherapy according to the approved SMPC
* Informed consent to data collection
Exclusion Criteria
* Any other tumour disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vitoria-Gasteiz, Alava, Spain
Alicante, Alicante, Spain
Elche, Alicante, Spain
Almería, Almeria, Spain
Palma de Mallorca, Balearic Islands, Spain
Palma de Mallorca, Balearic Islands, Spain
Badalona, Barcelona, Spain
Barcelona, Barcelona, Spain
Barcelona, Barcelona, Spain
Barcelona, Barcelona, Spain
Sabadell, Barcelona, Spain
Cadiz, Cadiz, Spain
Jerez de la Frontera, Cadiz, Spain
Puerto Real, Cadiz, Spain
Santander, Cantabria, Spain
Castellon, Castellon, Spain
Girona, Girona, Spain
Huelva, Huelva, Spain
Jaén, Jaen, Spain
Ferrol, La Coruña, Spain
Logroño, La Rioja, Spain
Las Palmas, Las Palmas, Spain
Las Palmas de Gran Canaria, Las Palmas, Spain
León, Leon, Spain
Lleida, Lerida, Spain
Alcorcón, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Málaga, Malaga, Spain
Málaga, Malaga, Spain
Cartagena, Murcia, Spain
Lorca, Murcia, Spain
Pamplona, Navarre, Spain
Gijón, Principality of Asturias, Spain
Oviedo, Principality of Asturias, Spain
Seville, Sevilla, Spain
Seville, Sevilla, Spain
Seville, Sevilla, Spain
Tarragona, Tarragona, Spain
San Cristóbal de La Laguna, Tenerife, Spain
Santa Cruz de Tenerife, Tenerife, Spain
Alzira, Valencia, Spain
Valencia, Valencia, Spain
Valencia, Valencia, Spain
Valencia, Valencia, Spain
Valencia, Valencia, Spain
Valladolid, Valladolid, Spain
Bilbao, Vizcaya, Spain
Zaragoza, Zaragoza, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML25372
Identifier Type: -
Identifier Source: org_study_id